LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Apellis Pharmaceuticals Inc

Fechado

SetorSaúde

17.41 -5.38

Visão Geral

Variação de preço das ações

24h

Atual

Mín

17.35

Máximo

18.37

Indicadores-chave

By Trading Economics

Rendimento

-56M

-92M

Vendas

-46M

167M

EPS

-0.74

Margem de lucro

-55.292

Funcionários

705

EBITDA

-56M

-80M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+93.75% upside

Dividendos

By Dow Jones

Próximos Ganhos

31 de jul. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-333M

2.2B

Abertura anterior

22.79

Fecho anterior

17.41

Sentimento de Notícias

By Acuity

50%

50%

162 / 380 Ranking em Healthcare

Apellis Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

27 de jun. de 2025, 20:51 UTC

Ganhos

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 de jun. de 2025, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

27 de jun. de 2025, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

27 de jun. de 2025, 20:48 UTC

Conversa de Mercado

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

27 de jun. de 2025, 20:46 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

27 de jun. de 2025, 20:46 UTC

Conversa de Mercado

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

27 de jun. de 2025, 19:31 UTC

Conversa de Mercado

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

27 de jun. de 2025, 19:19 UTC

Conversa de Mercado

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

27 de jun. de 2025, 19:16 UTC

Conversa de Mercado

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

27 de jun. de 2025, 18:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

27 de jun. de 2025, 18:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

27 de jun. de 2025, 18:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

27 de jun. de 2025, 18:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 de jun. de 2025, 18:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 de jun. de 2025, 18:42 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 de jun. de 2025, 18:42 UTC

Conversa de Mercado

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

27 de jun. de 2025, 18:39 UTC

Conversa de Mercado
Ganhos

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

27 de jun. de 2025, 18:29 UTC

Conversa de Mercado

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

27 de jun. de 2025, 18:18 UTC

Conversa de Mercado

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

27 de jun. de 2025, 18:16 UTC

Conversa de Mercado

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

27 de jun. de 2025, 17:16 UTC

Conversa de Mercado

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

27 de jun. de 2025, 17:08 UTC

Ganhos

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

27 de jun. de 2025, 16:52 UTC

Aquisições, Fusões, Aquisições de Empresas

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

27 de jun. de 2025, 16:22 UTC

Ganhos

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 de jun. de 2025, 16:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

27 de jun. de 2025, 16:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

27 de jun. de 2025, 16:20 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

27 de jun. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

27 de jun. de 2025, 15:59 UTC

Conversa de Mercado

Gold Futures Slump on Improving Risk Appetite -- Market Talk

27 de jun. de 2025, 15:56 UTC

Conversa de Mercado

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Comparação entre Pares

Variação de preço

Apellis Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

93.75% parte superior

Previsão para 12 meses

Média 35.65 USD  93.75%

Máximo 60 USD

Mínimo 18 USD

Com base em 18 analistas de Wall Street que oferecem metas de preço de 12 meses para Apellis Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

18 ratings

10

Comprar

8

Manter

0

Vender

Sentimento

By Acuity

162 / 380 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.